2. Disease Areas
  3. Metabolic or Endocrine Disease

Metabolic or Endocrine Disease

Metabolic or endocrine diseases involve disruptions in the body's normal processing and distribution of macronutrients, typically caused by abnormal biochemical reactions or inherited genetic defects, leading to diverse symptoms such as lethargy, weight loss, jaundice, and seizures. Endocrine diseases are noncommunicable disorders caused by hormonal imbalances due to overproduction or underproduction of hormones by endocrine glands, leading to conditions such as Type-2 diabetes and hypothyroidism, often worsened by a sedentary lifestyle.

 

Metabolic or Endocrine Disease (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17386
    Rosiglitazone 122320-73-4 99.94%
    Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.
    Rosiglitazone
  • HY-N0385
    Gomisin J 66280-25-9 99.97%
    Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.
    Gomisin J